UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Novo Nordisk Korea issues weight loss data of Saxenda
  • By Marian Chu
  • Published 2018.05.29 11:16
  • Updated 2018.05.29 11:16
  • comments 0

Novo Nordisk Korea published real-world study findings on its obesity treatment Saxenda (ingredient: liraglutide 3 mg) that showed notable weight loss for its takers.

Saxenda

The Danish pharmaceutical firm published its findings at the 23rd International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2018) held in Baltimore, Md., and the 25th European Congress on Obesity (ECO 2018) that opened in Vienna.

The study was carried out on overweight and obese patients at six weight management clinics in Canada.

Results showed that those who took Saxenda as an adjunct therapy to diet and exercise lost an average of 8.1 kg in six months, down 7.1 percent from the pre-treatment situation. Around 63 percent lost than more 5 percent of their weight and 35 percent lost more than 10 percent.

"Weight loss of five to 10 percent can have significant health benefits, such as reducing the risk of developing cardiovascular disease and type 2 diabetes. In this study we see hard evidence of meaningful weight loss,” said Dr. Sean Wharton of the Wharton Medical Clinic, Toronto, and lead investigator.

People taking Saxenda also experienced the improved risk of cardiovascular events such as blood glucose and hypertension, according to the study.

Results of the study were consistent with results reported in the SCALE trial for Saxenda, Novo Nordisk Korea said.

yjc@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Marian Chu
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top